ResearcherHospital of the University of PennsylvaniaActive in the last 2 years
Zain M. Hannan
Matched on ORCID iD 0000-0002-3714-9779; OpenAlex author ID A5033800199, A5118363978. Sources: OpenAlex.
Their work
- Papers
- 3
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 11
2021: 2 papers · 2022: none · 2023: none · 2024: none · 2025: none · 2026: 1 paper
Papers 3
- Long-Term Outcomes of Patients With BRCA+ or PALB2+ Pancreatic Cancer Treated With Maintenance Rucaparib: A Secondary Analysis of a Nonrandomized Clinical Tria… Co-author DOI 10.1001/jamaoncol.2026.0870↗
- Clinical Characteristics of Patients With Pancreatic Cancer and Pathogenic ATM Alterations. Co-author DOI 10.1093/jncics/pkaa121↗
- Phase II Study of Maintenance Rucaparib in Patients With Platinum-Sensitive Advanced Pancreatic Cancer and a Pathogenic Germline or Somatic Variant in BRCA1, B… Co-author DOI 10.1200/jco.21.00003↗
Closest collaborators
The 11 strongest of 11 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Susan M. Domchek · 3 shared papers, 2021–2026 · strength 0.51
- Paper Long-Term Outcomes of Patients With BRCA+ or PALB2+ Pancreatic Cancer Treated With Maintenance Rucaparib: A Secondary A… DOI 10.1001/jamaoncol.2026.0870↗
- Paper Clinical Characteristics of Patients With Pancreatic Cancer and Pathogenic ATM Alterations. DOI 10.1093/jncics/pkaa121↗
- Paper Phase II Study of Maintenance Rucaparib in Patients With Platinum-Sensitive Advanced Pancreatic Cancer and a Pathogenic… DOI 10.1200/jco.21.00003↗
- Kim A. Reiss · 3 shared papers, 2021–2026 · strength 0.51
- Paper Long-Term Outcomes of Patients With BRCA+ or PALB2+ Pancreatic Cancer Treated With Maintenance Rucaparib: A Secondary A… DOI 10.1001/jamaoncol.2026.0870↗
- Paper Clinical Characteristics of Patients With Pancreatic Cancer and Pathogenic ATM Alterations. DOI 10.1093/jncics/pkaa121↗
- Paper Phase II Study of Maintenance Rucaparib in Patients With Platinum-Sensitive Advanced Pancreatic Cancer and a Pathogenic… DOI 10.1200/jco.21.00003↗
- Katherine L. Nathanson · 2 shared papers, 2021–2026 · strength 0.34
- Paper Long-Term Outcomes of Patients With BRCA+ or PALB2+ Pancreatic Cancer Treated With Maintenance Rucaparib: A Secondary A… DOI 10.1001/jamaoncol.2026.0870↗
- Paper Phase II Study of Maintenance Rucaparib in Patients With Platinum-Sensitive Advanced Pancreatic Cancer and a Pathogenic… DOI 10.1200/jco.21.00003↗
- Robert H. Vonderheide · 2 shared papers, 2021–2026 · strength 0.34
- Paper Long-Term Outcomes of Patients With BRCA+ or PALB2+ Pancreatic Cancer Treated With Maintenance Rucaparib: A Secondary A… DOI 10.1001/jamaoncol.2026.0870↗
- Paper Phase II Study of Maintenance Rucaparib in Patients With Platinum-Sensitive Advanced Pancreatic Cancer and a Pathogenic… DOI 10.1200/jco.21.00003↗
- Mark H. O’Hara · 2 shared papers, 2021–2026 · strength 0.34
- Paper Long-Term Outcomes of Patients With BRCA+ or PALB2+ Pancreatic Cancer Treated With Maintenance Rucaparib: A Secondary A… DOI 10.1001/jamaoncol.2026.0870↗
- Paper Phase II Study of Maintenance Rucaparib in Patients With Platinum-Sensitive Advanced Pancreatic Cancer and a Pathogenic… DOI 10.1200/jco.21.00003↗
- Timothy J. Brown · 1 shared paper, 2026 · strength 0.24
- Ronac Mamtani · 1 shared paper, 2021 · strength 0.17
- Shun Yu · 1 shared paper, 2021 · strength 0.17
- Max Miller Wattenberg · 1 shared paper, 2021 · strength 0.11
- Thomas Benjamin Karasic · 1 shared paper, 2021 · strength 0.11
- Gregory Lawrence Beatty · 1 shared paper, 2021 · strength 0.11
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.